Organogenesis Holdings Inc. (NASDAQ:ORGO) saw a downside of -4.39% to close Monday at $3.70 after subtracting -$0.17 on the day. The 5-day average trading volume is 1,211,100 shares of the company’s common stock. It has gained $4.41 in the past week and touched a new high 1 time within the past 5 days. An average of 870,405 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 873,418.
ORGO’s 1-month performance is 16.72% or $0.53 on its low of $3.12 reached on 07/10/23. The company’s shares have touched a 52-week low of $1.79 and high of $6.52, with the stock’s rally to the 52-week high happening on 07/19/23. YTD, ORGO has achieved 37.55% or $1.01 and has reached a new high 18 times. However, the current price is down -43.25% from the 52-week high price.
Insider Transactions
ORGO stock investors last saw insider trading activity on Apr 12.ERANI ALBERT (10% Owner) most recently sold 25,000 shares at $2.07 per share on Apr 12. This transaction cost the insider $51,772. 10% Owner, ERANI ALBERT, sold 25,000 shares at a price of $2.07 on Apr 12.
Valuation Metrics
Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.15 while the price-to-book (PB) in the most recent quarter is 1.84.
Organogenesis Holdings Inc.’s quick ratio for the period ended March 30 was 2.50, with the current ratio over the same period at 2.90. As well, the company’s long term debt to equity for the quarter ending March 30 was 0.25, while the total debt to equity was 0.27. In terms of profitability, the gross margin trailing 12 months is 76.90%. The firm’s gross profit as reported stood at $345.87 million against revenue of $450.89 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 103.03% to -$2.97 million, while revenue of $6.49 million was 318.52% off the previous quarter. Analysts expected ORGO to announce -$0.02 per share in earnings in its latest quarter, but it posted -$0.02, representing a 0.00% surprise. EBITDA for the quarter stood at more than $1.86 million. ORGO stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 182.41 million, with total debt at $124.31 million. Shareholders hold equity totaling $131.26 million.
Let’s look briefly at Organogenesis Holdings Inc. (ORGO) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 32.77% to suggest the stock is trending Neutral, with historical volatility in this time period at 56.77%.
The stock’s 5-day moving average is $4.06, reflecting a -13.35% or -$0.57 change from its current price. ORGO is currently trading +12.12% above its 20-day SMA, +71.30% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -7.27% and SMA200 by+11.45%.
Stochastic %K and %D was 31.72% and 48.52% and the average true range (ATR) pointed at 0.26. The RSI (14) points at 41.84%, while the 14-day stochastic is at 19.19% with the period’s ATR at 0.25. The stock’s 9-day MACD Oscillator is pointing at -0.18 and -0.24 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Organogenesis Holdings Inc. (NASDAQ: ORGO), Morgan Stanley launched coverage with an Equal-weight rating. Analysts offering their rating for ORGO stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate ORGO as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is ORGO’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $10.00, with their median price target at $7.50. Looking at these predictions, the average price target given by analysts is for Organogenesis Holdings Inc. (ORGO) stock is $7.50.
